EICHORPublic-registry site landscape for NCT05789524, “The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B”, a Hemophilia a study sponsored by ApcinteX Ltd. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05789524 (registry record) |
| Study title | The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B |
| Official title | A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B |
| Sponsor | ApcinteX Ltd |
| Condition(s) | Hemophilia a; Hemophilia B |
| Phase | PHASE2 |
| Listed sites | 59 |
| Site countries | United States, Armenia, Australia, Belgium, Canada, France, Germany, India, Italy, Poland, South Africa, Spain |
Patient-friendly overview of this study: eichor.com/study/NCT05789524.
Eichor generates a preliminary site-risk snapshot for NCT05789524 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Hemophilia a trials
← Eichor home · All tracked trials · Hemophilia a studies · Weekly briefs
